Quantcast
Last updated on April 17, 2014 at 12:46 EDT

Latest cyclophosphamide Stories

2010-07-15 13:55:37

Investigators have made a major advance in treating people with a severe form of vasculitis, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare but devastating disease of blood vessels. In a six-month study, a new treatment strategy provided the same benefits as the current standard of care used for more than 40 years but required less frequent treatments. Early results also suggest that patients with disease relapses"”typically recurrences of fever, fatigue,...

2010-07-15 13:30:56

Researchers have reported that Rituximab, a drug that is FDA approved to treat B cell lymphoma and rheumatoid arthritis, can also treat severe vasculitis as well as the current standard therapy. Infertility and the development of cancers have been associated with the traditionally used medication, cyclophosphamide, and the risk of these complications is expected to be much lower with Rituximab. The news will be published in the July 14 issue of the New England Journal of Medicine. "The reason...

2009-11-18 11:51:00

MISSISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that results from a study evaluating nimotuzumab were presented today in a poster at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts. The reported results demonstrate that...

2009-11-11 02:00:00

Finland, November 11 /PRNewswire/ -- - This is a third party press release. It will be issued by the Finnish Breast Cancer Group on Wednesday 11 November 2009. - FinXX, a Large, Phase III Randomised Study in Women With Early Breast Cancer Shows that Adding Capecitabine (Xeloda(R)) to a Treatment Regimen Containing Standard Agents Allows More Women to Live Cancer-Free for Longer An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology...

2009-10-18 08:33:10

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. The news will be presented October 18 at the annual meeting of the American College of Rheumatology in Philadelphia. "The reason this is a big deal is that this is a disease where people would come in and be told 'listen, we are probably...

2009-08-11 07:00:00

WALTHAM, Mass., Aug. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of premium-priced biologics will drive the systemic lupus erythematosus drug market to more than quadruple from approximately $420 million in 2008 to nearly $2 billion in 2018. The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the primary drivers of market growth will be the entry...

2008-12-07 19:48:00

SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported the Phase I results from a randomized, multi-center, Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide and lenalidomide (VcDCR) in patients with previously untreated multiple myeloma (MM). The preliminary analysis of the safety data showed that the combination of four drugs was generally well tolerated in patients who had received no prior therapies and response rates...

2008-11-05 09:00:34

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive and Medical Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 4:30 pm ET at the New York Palace Hotel in New York City. Dr. Lewis will provide an overview of the Company and its clinical development programs. The presentation will be webcast live and can be accessed by visiting the Investor Relations section at...

2008-10-27 09:00:41

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced results of a series of studies demonstrating Protectan CBLB612's ability to substantially reduce myelosuppression (the most common rate limiting adverse effect of chemotherapy) caused by a widely used chemotherapeutic drug, cyclophosphamide (Cytoxan, Neosar, CTX). Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, stated: "Our previous studies established Protectan CBLB612's activity as a potent...

2008-10-27 09:00:41

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive and Medical Officer, will present at the Oppenheimer & Co. 19th Annual Healthcare Conference on Monday, November 3, 2008 at 3:20 pm ET at the Waldorf-Astoria Hotel in New York City. Dr. Lewis will provide an overview of the Company and its clinical development programs. The presentation will be webcast live and can be accessed by visiting the Investor Relations section at...